The finding that low-grade gliomas with an IDH mutation frequently have a methylated MGMT promoter could be extrapolated to high-grade gliomas, which might potentially explain the nonsignificant trend in this study [26,27]. This evidence concerns the gene IDH2 and central nervous system cancer.